FDA Approves Companion Diagnostic for Colorectal Cancer Treatment
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
Read More
Search Results for: lung cancer
New Standards Issued for Liquid Biopsy Cancer Recurrence Tests
The BLOODPAC Consortium has released new analytical validation standards for liquid biopsy MRD tests, offering industry-wide protocols for tumor-informed ctDNA assay development, as detailed in JCO Precision Oncology.
Read More
ctDNA Testing May Better Predict Breast Cancer Recurrence Than Current Standard
A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Read More
Labcorp Expands MRD Testing Portfolio for Three Cancer Types
Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.
Read More
CTC Counts Show Value in Guiding Metastatic Breast Cancer Treatment Decisions
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More